Literature DB >> 18925530

Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies.

Branka Mitic1, Gordana Lazarevic, Predrag Vlahovic, Milena Rajic, Vladisav Stefanovic.   

Abstract

AIM: The aim of the present study was to investigate the value of the urine cell glycoprotein 1 (PC-1), aminopeptidase N (APN), N-acetyl-beta-D-glucosaminidase (NAGA), and dipeptidylpeptidase IV (DPP IV) in the evaluation of tubular damage in patients with primary glomerulonephritis, diabetic nephropathy, and lupus nephritis. SUBJECTS AND METHODS: PC-1, APN, NAGA, and DPP IV activities were determined in serum, urine, and lymphocytes of 178 subjects, including 10 patients with membranous nephropathy, 38 with IgA nephropathy, 29 with lupus nephritis, 51 with diabetic nephropathy, and 50 control subjects.
RESULTS: Urinary PC-1 excretion in IgA nephropathy group was significantly higher (p < 0.05) than in controls. Urinary NAGA excretion was markedly (p < 0.01) higher in membranous nephropathy group, and APN excretion in diabetic nephropathy group was significantly higher (p < 0.01) than in healthy controls. Urinary APN activity was significantly (p < 0.01) higher in both type 1 and type 2 diabetic patients with microalbuminuria, as well as urinary NAGA and DPP IV activities in type 2 diabetics with microalbuminuria (p < 0.01 and p < 0.05, respectively) compared to controls. Serum PC-1 and APN activities were significantly higher than the control level in membranous nephropathy group, as well as serum PC-1 and DPP IV activities in IgA nephropathy patients (p < 0.05). However, significantly lower serum DPP IV and APN activity was observed in type 2 diabetics with microalbuminuria compared to controls (p < 0.05).
CONCLUSION: Damage of tubules in primary glomerulonephritis, lupus nephritis, and diabetic nephropathy is accompanied by a release of several tubular enzymes, with possible diagnostic and prognostic significance. Increased serum PC-1, APN, and DPP IV activities could be also of diagnostic significance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18925530     DOI: 10.1080/08860220802359048

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  10 in total

Review 1.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

2.  Discrimination of agonist and antagonist forms of CXCL10 in biological samples.

Authors:  A Casrouge; A Bisiaux; L Stephen; M Schmolz; J Mapes; C Pfister; S Pol; V Mallet; M L Albert
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 3.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

4.  Tubular marker excretion in children from families with Balkan nephropathy.

Authors:  Vladisav Stefanovic; Rade Cukuranovic; Vidosava Djordjevic; Ivan Jovanovic; Nevenka Lecic; Milena Rajic
Journal:  Pediatr Nephrol       Date:  2009-08-25       Impact factor: 3.714

Review 5.  Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4.

Authors:  A Casrouge; A V Sauer; R Barreira da Silva; M Tejera-Alhambra; S Sánchez-Ramón; C Cancrini; M A Ingersoll; A Aiuti; M L Albert
Journal:  Clin Exp Immunol       Date:  2018-09-24       Impact factor: 4.330

Review 6.  Dipeptidyl peptidase-4 and kidney fibrosis in diabetes.

Authors:  Sen Shi; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2016-02-13

Review 7.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

8.  Activity screening and structure-activity relationship of the hit compounds targeting APN/CD13.

Authors:  Xuejian Wang; Fanbo Jing; Huawei Zhu; Hao Fang; Jian Zhang; Wenfang Xu
Journal:  Fundam Clin Pharmacol       Date:  2011-04       Impact factor: 2.748

9.  Urinary aminopeptidase activities as early and predictive biomarkers of renal dysfunction in cisplatin-treated rats.

Authors:  Andrés Quesada; Félix Vargas; Sebastián Montoro-Molina; Francisco O'Valle; María Dolores Rodríguez-Martínez; Antonio Osuna; Isabel Prieto; Manuel Ramírez; Rosemary Wangensteen
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

Review 10.  Aminopeptidases in Cardiovascular and Renal Function. Role as Predictive Renal Injury Biomarkers.

Authors:  Félix Vargas; Rosemary Wangesteen; Isabel Rodríguez-Gómez; Joaquín García-Estañ
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.